Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersDermatology Physician in Pittsburgh, PA
NPI: 1316274590Primary Practice Location
UPMC PRESBYTERIAN SHADYSIDE
3459 5th Ave, Pittsburgh, PA
Primary Employer
University of Pittsburgh Physicians
chp.edu
HQ Phone
Get M.D., PH.D. Oleg's Phone Numberphone_androidMobile
Get M.D., PH.D. Oleg's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 58 | 63 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 55 | 104 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 30 | 30 |
| 4 | 99203New patient outpatient visit, total time 30-44 minutes | 27 | 27 |
| 5 | 17110Destruction of up to 14 skin growths | 24 | 25 |
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Authors: David Fisher, Tatyana Feldman, Timothy Kuzel
Publication Date: 2017-01-16
Authors: Kruglov, Oleg, Wu, Xuesong, Hwang, Sam T, Akilov, Oleg E
Journal: Blood Adv
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Authors: David Fisher
Publication Date: 2021-03-10
Lead Sponsor: Oleg E. Akilov, MD, PhD
Collaborators: Mallinckrodt
Intervention / Treatment: DEVICE: Extracorporeal photopheresis (ECP), DRUG: Methoxsalen Injection
Lead Sponsor: University of Pittsburgh
Intervention / Treatment: OTHER: Blood draw, skin biopsy or urine collection
Lead Sponsor: Falo, Louis, MD
Intervention / Treatment: DRUG: Micro needle array-Doxorubicin (MNA-D)
